<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549897</url>
  </required_header>
  <id_info>
    <org_study_id>AI-ABL-001</org_study_id>
    <nct_id>NCT03549897</nct_id>
  </id_info>
  <brief_title>Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base</brief_title>
  <official_title>A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Amneal Ireland Limited) to PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base (Teva Respiratory, LLC) in Patients With Stable, Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Ireland Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amneal Ireland Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, single-dose, double-blind, double-dummy, four-period, four-sequence,
      four-treatment, placebo and active controlled, comparative, multiple-center, crossover-design
      bronchoprovocation study has been designed to evaluate the pharmacodynamic equivalence of
      albuterol sulfate HFA inhalation aerosol, eq 90 mcg base (Amneal Ireland Limited) to PROAIR®
      HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory, LLC) in
      patients with stable mild asthma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Pharmacodynamic Endpoint Post-dose PC20</measure>
    <time_frame>6 weeks</time_frame>
    <description>Provocative concentration of the methacholine challenge agent required to reduce the FEV1 by 20% following administration of differing doses of albuterol or placebo by inhalation. The 20% reduction in FEV1 will be determined relative to the post-saline FEV1 measure before the placebo or albuterol administration.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mcg Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Product</description>
    <arm_group_label>Placebo Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg Reference Product</intervention_name>
    <description>90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]</description>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 mcg Reference Product</intervention_name>
    <description>180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]</description>
    <arm_group_label>180 mcg Reference Product</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg Test Product</intervention_name>
    <description>90 mcg Test Product - ALBUTEROL SULFATE HFA [AMNEAL IRELAND LIMITED]</description>
    <arm_group_label>90 mcg Test Product</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female subjects (18-65 years of age).

          -  Stable mild asthmatics based on National Asthma Education and Prevention Program
             (NAEPP) guidelines.

          -  FEV1 ≥ 80% of predicted.

          -  Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline)
             PC20 ≤ 8 mg/mL.

          -  Nonsmokers for at least six months prior to the study and a maximum smoking history of
             five pack-years (the equivalent of one pack per day for five years).

          -  Written informed consent

        Exclusion Criteria:

          -  Evidence of upper or lower respiratory tract infection (e.g., pneumonia, bronchitis,
             sinusitis) within six weeks prior to the study.

          -  History of seasonal asthma exacerbations, in which case the subject should be studied
             outside of the relevant allergen season.

          -  History of cystic fibrosis, bronchiectasis or other respiratory diseases.

          -  History of cardiovascular, renal, neurologic, liver or endocrine dysfunction,
             including ECG with evidence of ischemic heart disease.

          -  Treatment in an emergency room or hospitalization for acute asthmatic symptoms or need
             for daily oral corticosteroids within past three months.

          -  Known intolerance or hypersensitivity to any component of the albuterol MDI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irshad Haque</last_name>
    <role>Study Director</role>
    <affiliation>Amneal Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irshad Haque</last_name>
    <phone>631-952-0214</phone>
    <email>ihaque@amneal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amneal Pharmaceuticals LLC</name>
      <address>
        <city>Brookhaven</city>
        <state>New York</state>
        <zip>11719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irshad Haque</last_name>
      <phone>631-952-0214</phone>
      <email>ihaque@amneal.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

